CRISPR Therapeutics AGÂ (CRSP)Â
Largest Insider Buys in Sector
CRSP Stock Price History Chart
CRSP Stock Performance
About CRISPR Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Insider Activity of CRISPR Therapeutics AG
Over the last 12 months, insiders at CRISPR Therapeutics AG have bought $0 and sold $12.52M worth of CRISPR Therapeutics AG stock.
On average, over the past 5 years, insiders at CRISPR Therapeutics AG have bought $0 and sold $48.97M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 54,922 shares for transaction amount of $1.37M was made by Vertex Pharmaceuticals (Europe) Ltd (10 percent owner) on 2018‑12‑27.
List of Insider Buy and Sell Transactions, CRISPR Therapeutics AG
| 2024-12-02 | Sale | Chief Executive Officer | 15,000 0.0175% | $55.10 | $826,565 | -24.73% | ||
| 2024-11-11 | Sale | Chief Executive Officer | 30,000 0.0356% | $55.62 | $1.67M | -17.95% | ||
| 2024-10-14 | Sale | Chief Executive Officer | 4,293 0.005% | $46.28 | $198,680 | +0.16% | ||
| 2024-10-14 | Sale | General Counsel and Secretary | 1,089 0.0013% | $46.28 | $50,399 | +0.16% | ||
| 2024-06-21 | Sale | Chief Operating Officer | 3,366 0.0036% | $56.09 | $188,799 | -14.90% | ||
| 2024-04-15 | Sale | Chief Executive Officer | 19,582 0.0235% | $59.91 | $1.17M | -15.10% | ||
| 2024-03-15 | Sale | Chief Executive Officer | 20,000 0.0236% | $72.48 | $1.45M | -29.92% | ||
| 2024-03-15 | Sale | Chief Financial Officer | 3,524 0.0042% | $72.69 | $256,160 | -29.92% | ||
| 2024-03-12 | Sale | Chief Executive Officer | 4,583 0.0054% | $74.44 | $341,159 | -32.05% | ||
| 2024-03-12 | Sale | General Counsel and Secretary | 1,146 0.0013% | $74.44 | $85,308 | -32.05% | ||
| 2024-03-11 | Sale | Chief Executive Officer | 9,802 0.0119% | $78.26 | $767,105 | -33.39% | ||
| 2024-03-11 | Sale | General Counsel and Secretary | 2,801 0.0034% | $78.26 | $219,206 | -33.39% | ||
| 2024-02-20 | Sale | Chief Executive Officer | 6,370 0.0081% | $79.67 | $507,498 | -32.15% | ||
| 2024-02-20 | Sale | General Counsel and Secretary | 1,913 0.0024% | $79.67 | $152,409 | -32.15% | ||
| 2024-02-15 | Sale | Chief Executive Officer | 20,000 0.0256% | $80.36 | $1.61M | -36.51% | ||
| 2024-01-29 | Sale | Chief Executive Officer | 50,000 0.0582% | $60.51 | $3.03M | -16.61% | ||
| 2024-01-16 | Sale | Chief Executive Officer | 20,000 0.0249% | $62.50 | $1.25M | -13.20% | ||
| 2023-05-30 | Sale | Chief Executive Officer | 25,000 0.0319% | $64.88 | $1.62M | -11.56% | ||
| 2023-04-25 | Sale | Chief Executive Officer | 25,000 0.033% | $50.67 | $1.27M | +19.36% | ||
| 2023-03-29 | Sale | Chief Executive Officer | 25,000 0.0316% | $44.46 | $1.11M | +27.58% |
Insider Historical Profitability
| Kulkarni Samarth | Chief Executive Officer | 181540 0.2127% | $43.91 | 0 | 43 | |
| KASINGER JAMES R. | General Counsel and Secretary | 62597 0.0733% | $43.91 | 0 | 5 | |
| Bruno Julianne | Chief Operating Officer | 6745 0.0079% | $43.91 | 0 | 1 | |
| Prasad Raju | Chief Financial Officer | 6476 0.0076% | $43.91 | 0 | 1 | |
| BAYER AKTIENGESELLSCHAFT | 10 percent owner | 5632802 6.5994% | $43.91 | 1 | 0 | +77.06% |
| Vertex Pharmaceuticals (Europe) Ltd | 10 percent owner | 5380940 6.3043% | $43.91 | 4 | 0 | +63.29% |
| CELGENE CORP /DE/ | 10 percent owner | 4173019 4.8891% | $43.91 | 1 | 21 | +31.44% |
| GLAXOSMITHKLINE PLC | 10 percent owner | 3220627 3.7733% | $43.91 | 1 | 0 | +31.44% |
| George Simeon | director | 3220627 3.7733% | $43.91 | 1 | 0 | +31.44% |
| EMSTER KURT VON | director | 1171268 1.3723% | $43.91 | 2 | 39 | +54.25% |
| Woiwode Thomas | director | 640014 0.7498% | $43.91 | 1 | 11 | +31.44% |
| Novak Rodger | President | 573007 0.6713% | $43.91 | 0 | 41 | |
| Lundberg Sven Ante | Chief Scientific Officer | 505617 0.5924% | $43.91 | 1 | 0 | +31.44% |
| Bolzon Bradley J PhD | director | 148831 0.1744% | $43.91 | 1 | 30 | +31.44% |
| Versant Venture Capital IV, L.P. | 10 percent owner | 45171 0.0529% | $43.91 | 1 | 1 | +31.44% |
| Versant Venture Capital V, L.P. | 10 percent owner | 44582 0.0522% | $43.91 | 0 | 1 | |
| Ho Tony W | Executive VP, Head of R&D | 33964 0.0398% | $43.91 | 0 | 5 | |
| Dylan-Hyde Tyler | Chief Legal Officer | 25204 0.0295% | $43.91 | 0 | 18 | |
| TOMSICEK MICHAEL JOHN | Chief Financial Officer | 1891 0.0022% | $43.91 | 0 | 3 | |
| Klein Lawrence Otto | CBO & COO | 1050 0.0012% | $43.91 | 0 | 7 | |
| CAGNONI PABLO J | director | 0 0% | $43.91 | 0 | 5 |
Institutional Investor Ownership
| ARK Investment Management LLC | $555.98M | 9.61 | 8.16M | -4.44% | -$25.84M | 1.92 | |
| Capital International Investors | $534.17M | 9.23 | 7.84M | +27.75% | +$116.05M | 0.11 | |
| Sumitomo Mitsui Trust Holdings | $222.8M | 3.85 | 3.27M | -3% | -$6.88M | 0.15 | |
| Nikko Asset Management Americas Inc | $222.7M | 3.85 | 3.27M | -3% | -$6.88M | 1.67 | |
| T Rowe Price Investment Management Inc | $184.33M | 3.19 | 2.7M | -25.11% | -$61.81M | 0.11 | |
| BlackRock | $173.56M | 3 | 2.55M | +1.19% | +$2.04M | <0.01 | |
| Fidelity Investments | $152.66M | 2.64 | 2.24M | +21.73% | +$27.25M | 0.01 | |
| The Vanguard Group | $111.56M | 1.93 | 1.64M | +2.9% | +$3.15M | <0.01 | |
| Nea Management Company Llc | $180.41M | 1.87 | 1.59M | 0% | +$0 | 0.84 | |
| State Street | $101.91M | 1.76 | 1.5M | -14.73% | -$17.6M | <0.01 | |
| Ecor1 Capital Llc | $94.69M | 1.64 | 1.39M | New | +$94.69M | 0.66 | |
| Morgan Stanley | $74.02M | 1.28 | 1.09M | +162.89% | +$45.86M | 0.01 | |
| Sr One Capital Management Lp | $71.5M | 1.24 | 1.05M | New | +$71.5M | 19.64 | |
| Loomis, Sayles & Company | $69.88M | 1.21 | 1.03M | -3.94% | -$2.87M | 0.1 | |
| Dimensional Fund Advisors | $63.46M | 1.1 | 931,055 | +19.45% | +$10.33M | 0.02 | |
| Geode Capital Management | $62M | 1.07 | 909,298 | +2.89% | +$1.74M | 0.01 | |
| Bank of America | $58.84M | 1.02 | 863,214 | +24.89% | +$11.73M | 0.01 | |
| Credit Suisse | $49.03M | 0.85 | 719,309 | -17.9% | -$10.69M | 0.05 | |
| Charles Schwab | $45.61M | 0.79 | 669,192 | +2.48% | +$1.1M | 0.01 | |
| Contrarius Investment Management Ltd | $45.4M | 0.78 | 666,000 | +264.08% | +$32.93M | 2.62 | |
| Bellevue Group | $42.26M | 0.73 | 619,950 | -31.15% | -$19.12M | 0.65 | |
| T. Rowe Price | $40.91M | 0.71 | 600,234 | -30.56% | -$18M | 0.01 | |
| Versant Ventures | $33.98M | 0.59 | 498,558 | 0% | +$0 | 32.95 | |
| Federated Hermes | $30.51M | 0.53 | 447,606 | -11.91% | -$4.12M | 0.07 | |
| Avoro Capital Advisors Llc | $28.6M | 0.49 | 419,580 | New | +$28.6M | 0.34 | |
| Baillie Gifford Co | $26.99M | 0.47 | 395,915 | -6.35% | -$1.83M | 0.02 | |
| JPMorgan Chase | $26.77M | 0.46 | 392,750 | -15.22% | -$4.81M | <0.01 | |
| UBS | $21.84M | 0.38 | 320,377 | +3.05% | +$645,611.51 | 0.01 | |
| Squarepoint Ops LLC | $18.68M | 0.32 | 274,030 | +115.17% | +$10M | 0.07 | |
| Barclays | $17.47M | 0.3 | 256,331 | -18.1% | -$3.86M | 0.01 | |
| Vestmark Advisory Solutions Inc | $17.01M | 0.29 | 249,544 | +44.01% | +$5.2M | 0.99 | |
| Northern Trust | $16.58M | 0.29 | 243,278 | -2.86% | -$487,684.82 | <0.01 | |
| Citadel Advisors LLC | $16.16M | 0.28 | 237,100 | -13.26% | -$2.47M | 0.01 | |
| Integral Health Asset Management Llc | $15M | 0.26 | 220,000 | New | +$15M | 1.51 | |
| Wells Fargo | $14.75M | 0.26 | 216,394 | +28.5% | +$3.27M | <0.01 | |
| Armistice Capital Llc | $13.09M | 0.23 | 192,000 | +14.29% | +$1.64M | 0.04 | |
| Jane Street Capital | $11.93M | 0.21 | 175,072 | -63.14% | -$20.44M | 0.01 | |
| D. E. Shaw & Co. | $11.88M | 0.21 | 174,295 | +367.63% | +$9.34M | 0.01 | |
| Mirae Asset Global Investments Co Ltd | $7.45M | 0.2 | 166,546 | +86.1% | +$3.45M | 0.01 | |
| Td Asset Management Inc | $11.37M | 0.2 | 166,794 | -26.15% | -$4.03M | 0.01 | |
| Woodline Partners LP | $11.15M | 0.19 | 163,577 | +226.94% | +$7.74M | 0.1 | |
| Ameriprise Financial | $10.68M | 0.19 | 156,781 | +22.59% | +$1.97M | <0.01 | |
| Swiss National Bank | $10.15M | 0.18 | 148,900 | +0.13% | +$13,632.00 | 0.01 | |
| Nordea Investment Management Ab | $10.3M | 0.18 | 148,700 | +40.81% | +$2.99M | 0.01 | |
| Blair William Co Il | $10.08M | 0.17 | 147,890 | +8.19% | +$762,710.37 | 0.03 | |
| Capital International Sarl | $9.67M | 0.17 | 141,908 | +38.21% | +$2.67M | 0.32 | |
| Goldman Sachs | $9.04M | 0.16 | 132,697 | -29.27% | -$3.74M | <0.01 | |
| Capital International Ltd Ca | $8.64M | 0.15 | 126,770 | +33.64% | +$2.17M | 0.41 | |
| Rafferty Asset Management Llc | $8.42M | 0.15 | 123,574 | -16.13% | -$1.62M | 0.02 | |
| Tang Capital Management, LLC | $7.94M | 0.14 | 116,500 | -45.81% | -$6.71M | 0.03 |